Biological therapies for cartilage lesions in the hip: A new horizon

Jorge Chahla, Robert F. La Prade, Rodrigo Mardones, Johnny Huard, Marc J. Philippon, Shane Nho, Omer Mei-Dan, Cecilia Pascual-Garrido

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Treatment of hip cartilage disease is challenging and there is no clear algorithm to address this entity. Biomarkers are arising as promising diagnostic tools because they could play a role in the early assessment of the prearthritic joint and as a prognostic factor before and after treatment. The potential effect of biomarkers may be used to categorize individuals at risk of evolving to severe osteoarthritis to develop new measures for clinical progression of the disease and to develop new treatment options for the prevention of osteoarthritis progression. A trend toward a less invasive biological treatment will usher in a new treatment era. With the growth of surgical skills in hip arthroscopy, cartilage restoration techniques are evolving in a fast and exponential manner. Biological and surgical treatments have been proposed to treat these pathologies. Biological treatments include platelet-rich plasma stem cells or bone marrow aspirate concentration hyaluronic acid losartan and fish oil. Surgical treatments include microfracture alone or augmented direct repair, autologous chondrocyte implantation matrix-induced chondrocyte implantation, autologous matrix-induced chondrogenesis mosaicplasty osteochondral allograft transplantation and stem cells implanted in matrix (stem cells in membranes/expanded stem cells). This article reviews new evidence available on treatment options for chondral lesions and early osteoarthritis of the hip.

Original languageEnglish
Pages (from-to)e715-e723
Issue number4
StatePublished - Jul 1 2016


Dive into the research topics of 'Biological therapies for cartilage lesions in the hip: A new horizon'. Together they form a unique fingerprint.

Cite this